A Study to Test GlaxoSmithKline's (GSK) Herpes Zoster (HZ) Subunit Vaccine's Long-term Immune Response in Previously Vaccinated Kidney Transplant Adults and Then to Test if 2 Additional Doses of the Vaccine Are Safe and Able to Generate an Immune Response
Key facts
- Who runs it
- GlaxoSmithKline
- Where
- Belgium, Canada, Finland, Panama, South Korea, Spain, and Taiwan10 sites in 7 countriesChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 68 people enrolled
- Started
- 9 Dec 2019
- Ended
- 27 Jun 2024
- Type of study
- Interventional
- Treatments tested
- HZ/su vaccine (GSK1437173A)
- Record updated
- 18 July 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Inclusion criteria for enrolment; Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol or/and subjects' Legally Acceptable Representative(s) [LAR(s)] who, in the opinion of the investigator, can and will comply, with the requirements of the protocol; Written informed consent obtained from the subject/LAR(s) of the subject prior to performance of any study-specific procedure; Subjects who previously participated in study ZOSTER-041 and completed the full 2 dose HZ/su primary vaccination course
- Inclusion criteria for revaccination; Subjects receiving maintenance CIS therapy for the prevention of allograft rejection for a minimum of one month prior to the first revaccination; Subjects without an episode of allograft rejection within 90 days prior to the first revaccination visit; Female subjects of non-childbearing potential may be revaccinated. Non-childbearing potential is defined as pre-menarche, current bilateral tubal ligation or occlusion, hysterectomy, bilateral ovariectomy or post-menopause; Female subjects of childbearing potential may be revaccinated, if the subject:
- has practiced adequate contraception for 30 days prior to revaccination, and
- has a negative pregnancy test on the day of revaccination, and
- has agreed to continue adequate contraception up to 2 months after completion of the revaccination series
Who cannot take part
- Any other condition that, in the opinion of the investigator, would interfere with the evaluations required by the study; Prior/Concurrent clinical study experience
- Concurrently participating in another interventional vaccine or immunosuppressive clinical study, in which the subject is exposed to an investigational or a non-investigational vaccine/product (drug) at any time during the ZOSTER-073 study
- Any other condition that, in the opinion of the investigator, would interfere with the evaluations required by the study or make vaccination unsafe; Prior/Concomitant therapy
- Administration or planned administration of immunoglobulins and/or any blood products or plasma derivatives during the period starting 3 months before the first revaccination dose of study vaccine and ending at Visit 5 (Month 26)
- Use of anti-CD20 or other B-cell monoclonal antibody agents as maintenance and/or therapeutic immunosuppressive therapy for the prevention of allograft rejection within 9 months of first revaccination dose of study vaccine
- Evidence or high suspicion, in the opinion of the investigator, of noncompliance or nonadherence to use of maintenance immunosuppressive therapies
- Planned administration/administration of a live vaccine in the period starting 30 days before the first dose and ending 30 days after the last dose of study vaccine administration
- Planned administration/administration of a non-replicating or subunit vaccine, not foreseen by the study protocol, in the period starting 8 days before and ending 30 days after each dose of study vaccine; Other exclusion criteria for revaccination
- Significant underlying illness that, in the opinion of the investigator, is expected to prevent completion of the study
- History of confirmed HZ within one year before revaccination visit (Visit 3)
- Any additional confirmed or suspected immunosuppressive or immunodeficient condition
- History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine
- Any condition which, in the judgment of the investigator, would make intramuscular injection unsafe
- Vaccination against HZ since completion of study ZOSTER-041
- More than one organ transplanted
- Pregnant or lactating female
- Female planning to become pregnant or planning to discontinue contraceptive precautions up to 2 months post-revaccination Dose 2
This trial has no sites in United States.
It has sites in 7 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this study was to evaluate the long-term immune responses to the Herpes Zoster subunit (HZ/su) vaccine as well as safety up to 7 years after the 2-dose primary vaccination course from study ZOSTER-041 (NCT02058589). This study also assessed immune responses as well as safety after revaccination with 2 additional doses of the HZ/su administered at 6 to 8 years after the 2-dose primary vaccination course.
The group in the trial
- HZ/su GroupTreatment being tested
Participants with renal transplant who completed the 2-dose Herpes Zoster (HZ/su) vaccination course in the primary ZOSTER-041 (NCT02058589) study were enrolled in the current ZOSTER-073 (NCT04176939) study. 47 of these participants further received 1 or 2 additional doses of HZ/su vaccine in the revaccination phase of the current ZOSTER-073 (NCT04176939) study, first dose at Month 24 and second dose at Month 25.
Treatment: HZ/su vaccine (GSK1437173A)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Long-term Immunogenicity Study of Herpes Zoster Subunit Vaccine (GSK1437173A) and Immunogenicity and Safety Assessment of Revaccination With Two Additional Doses in Adults With Renal Transplant From Study ZOSTER-041
- Publications
- Long-term immunogenicity and safety of RZV primary vaccination and revaccination in kidney transplant recipients.The Journal of infection, 2026
- Record updated
- 18 July 2025